Client is a US based biopharmaceutical company, with immunology and immuno-oncology portfolio of monoclonal antibodies. The client was looking to increase the number of patient volunteers for an ongoing phase 3 drug trial against cytokine storms in hospitalized COVID-19 patients
- Short time window to comply with FDA’s requirement to increase number of patients recruited for drug trial from 300 to 500
- Filtering out relevant potential trial participants from the high volume of non-relevant website traffic owing to generic interest in COVID-19
- Promotion restrictions due to ongoing US election campaigns
- Building credibility with patients and caregivers to participate in the trial
We augmented traditional CRO model with digital strategies, AI/ML applications, and medical data mining for precise and effective targeting. Engaging data-driven digital campaigns were deployed for diverse patient recruitment based on geography, demography and interest-based signals.
Hyperlocal campaigns in English and Spanish on search and social platforms with programmatic, lookalike, and re-targeting formats were activated for better reach and engagement among diverse patient and HCP pool. We used our in-house omnichannel CRM platform, built in partnership with Microsoft, for NPI-level HCP outreach geo-fenced within 50 miles of trial sites.
The client was able to achieve trial recruitment target as per FDA guidelines within a short duration. They engaged and accelerated conversions and enrollment-volumes of potential participants visiting the landing page with 37K+ weekly unique users and qualification rate of 17%.
Broader reach, precise targeting, and multilingual campaigns resulted in higher engagement and enrollments of patients for the trial.